Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer
- PMID: 18224564
- DOI: 10.1080/00365520701491355
Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer
Abstract
Objective: We have recently shown that preoperative plasma tissue inhibitor of metalloproteinases-1 (TIMP-1) levels are significantly associated with prognosis of colorectal cancer patients. In addition, we have shown that measurement of plasma TIMP-1 yields information on specificity and sensitivity, which could be used for early detection of colorectal cancer. However, it is not clear whether the increased plasma TIMP-1 levels in colorectal cancer patients are derived from the tumour tissue itself in which it is mainly expressed by the stromal cells located in the vicinity of the cancer cells. The purpose of this study was to examine the association between blood TIMP-1 levels and tumour tissue TIMP-1 levels in colorectal cancer patients.
Material and methods: Preoperative EDTA plasma, citrate plasma and serum, as well as tumour tissue extracts from 49 colorectal cancer patients were measured with a TIMP-1 ELISA that measures total TIMP-1 levels (non-complexed and complexed TIMP-1).
Results: The median TIMP-1 level in the 49 tumour extracts was 18.7 ng/mg proteins (range 3.5-152.0 ng/mg protein). The median TIMP-1 value was 133.5 ng/ml (range 58.1-559.0 ng/ml) in EDTA plasma, 130.2 ng/ml (range 57.0-572.0 ng/ml) in citrate plasma and 207.2 ng/ml (range 72.6-828.0 ng/ml) in serum. No significant correlations were found between TIMP-1 content in the tumour extracts and in blood.However, EDTA and citrate plasma TIMP-1 levels (r=0.75; p <0.0001) as well as EDTA plasma and serum TIMP-1 levels (r= .064; p<0.0001) were highly correlated.
Conclusions: The lack of correlation between tumour tissue TIMP-1 and blood levels of TIMP-1 suggests that other sources than the tumour tissue itself may contribute to the increased levels of plasma TIMP-1 in patients with colorectal cancer. However, degradation of cell membranes, rapid secretion into the blood stream and other factors may be responsible for the observed lack of association between TIMP-1 concentrations in blood and tumour tissue extracts.
Similar articles
-
Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.Anticancer Res. 2000 Mar-Apr;20(2B):1085-91. Anticancer Res. 2000. PMID: 10810401
-
Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer.Scand J Clin Lab Invest. 2007;67(5):545-52. doi: 10.1080/00365510601166926. Scand J Clin Lab Invest. 2007. PMID: 17763191
-
Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer.Br J Cancer. 1999 May;80(3-4):495-503. doi: 10.1038/sj.bjc.6690384. Br J Cancer. 1999. PMID: 10408859 Free PMC article.
-
Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment.Scand J Gastroenterol. 2008;43(7):774-86. doi: 10.1080/00365520701878163. Scand J Gastroenterol. 2008. PMID: 18584515 Review.
-
Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection.Scand J Gastroenterol. 2008;43(2):242-8. doi: 10.1080/00365520701523439. Scand J Gastroenterol. 2008. PMID: 18224568 No abstract available.
Cited by
-
Banking of biological fluids for studies of disease-associated protein biomarkers.Mol Cell Proteomics. 2008 Oct;7(10):2061-6. doi: 10.1074/mcp.R800010-MCP200. Epub 2008 Aug 1. Mol Cell Proteomics. 2008. PMID: 18676364 Free PMC article. Review.
-
A Novel N-Sulfonylamidine-Based Derivative Inhibits Proliferation, Migration, and Invasion in Human Colorectal Cancer Cells by Suppressing Wnt/β-Catenin Signaling Pathway.Pharmaceutics. 2021 May 3;13(5):651. doi: 10.3390/pharmaceutics13050651. Pharmaceutics. 2021. PMID: 34063618 Free PMC article.
-
TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.Oncotarget. 2016 Sep 13;7(37):59441-59457. doi: 10.18632/oncotarget.11118. Oncotarget. 2016. PMID: 27509063 Free PMC article. Clinical Trial.
-
Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics.ScientificWorldJournal. 2014 Jan 14;2014:260348. doi: 10.1155/2014/260348. eCollection 2014. ScientificWorldJournal. 2014. PMID: 24550697 Free PMC article. Review.
-
Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1.J Gastrointest Surg. 2009 Oct;13(10):1781-90. doi: 10.1007/s11605-009-0948-x. Epub 2009 Jun 30. J Gastrointest Surg. 2009. PMID: 19565301
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous